Robots in the OR: Hype, Hope, or Holding Pattern in Cholecystectomy?

Abstract

Robotic-assisted cholecystectomy (RAC) is increasingly presented as the next step in minimally invasive biliary surgery, but its added value over laparoscopic cholecystectomy (LC) remains uncertain. Comparative evidence suggests that RAC may reduce conversion to open surgery in some settings, yet it has not demonstrated consistent improvement in postoperative outcomes and is generally associated with longer operative time, higher costs, and unresolved safety concerns during dissemination and learning. RAC may offer value in selected complex cases and within structured robotic training programs, but these roles require subgroup-specific evaluation. For an established, safe, and efficient procedure such as LC, noninferiority is not enough; routine adoption should depend on demonstrable clinical, educational, or operational added value.

1. Introduction

Technological innovation has long been the engine of progress in surgery—from the first laparoscope to today’s increasingly sophisticated robotic platforms. Among these, the robotic-assisted cholecystectomy (RAC) has emerged as a prominent alternative to the traditional laparoscopic cholecystectomy (LC), offering enhanced dexterity, tremor filtration, and a high-definition surgical view. Hospitals frequently present robotic platforms as markers of technological leadership, while patients may associate robotic surgery with greater precision, safety, or autonomy despite limited understanding of how the technology actually functions [1,2,3,4,5].

Yet, amid the enthusiasm, a fundamental question persists: Is robotic assistance meaningfully better or just impressively modern? As with many advances in medical technology, there is a risk of conflating innovation with improvement. In procedures such as cholecystectomy—one of the most commonly performed surgeries worldwide [6]—the clinical and operational stakes are high. Operative time, complication rates, and conversion to open procedures remain critical benchmarks.

This commentary reflects on current literature comparing RAC and LC, challenging the assumption that newer necessarily means better. Drawing on systematic reviews, large observational studies, and experimental training research, we explore whether robotic systems truly deliver measurable advantages—or whether, for now, they represent a solution in search of a problem [7].

Rather than asking whether robotic cholecystectomy is technically feasible, this Opinion article asks a more practical question: whether its routine use meaningfully improves value, efficiency, training, or patient-centred outcomes compared with an already mature laparoscopic standard.

For an established, safe, efficient, and comparatively inexpensive procedure such as LC, noninferiority alone is insufficient. Our position is that RAC should become routine only when it demonstrates clinically meaningful added value in defined patients, institutions, and surgeon-experience settings.

2. The Allure of Robots

Robotic-assisted surgery captures the imagination. It promises precision, reduced surgeon fatigue, and futuristic sophistication that appeals to both clinicians and patients alike. In cholecystectomy—one of the most frequently performed surgeries in the world—the idea of translating the surgeon’s movements through tremor-filtered, wristed instruments is seductive. Patients often ask, “Will the robot do my surgery?” with the expectation that this somehow ensures a safer or more advanced procedure. These capabilities are genuine platform advantages, but they are not themselves patient outcomes. Their clinical value depends on whether they reduce injury, conversion, recovery time, or resource use in actual practice.

From a training perspective, robotic platforms offer ergonomic advantages and enhanced visualisation that are particularly attractive to novice surgeons. The da Vinci Surgical System, the most widely adopted robotic platform in the U.S. [8,9,10,11], allows for immersive control via a console, removing the surgeon from the sterile field but increasing comfort and range of motion. Some institutions now incorporate robotic training into residency curricula, although the optimal pathway from simulation and supervised exposure to independent clinical practice remains unsettled.

Administratively, the appeal is no less potent. Hospitals market robotic surgery as a mark of technological leadership. For many institutions, purchasing a surgical robot is as much about prestige and patient recruitment as it is about outcomes [12,13]. Slick promotional videos, institutional branding, and patient-facing messaging help cultivate the idea that robotics equals better—even when data tells a more nuanced story.

Analyses of hospital websites have documented frequent claims of robotic superiority with limited discussion of comparative evidence or risk, while public surveys reveal persistent misconceptions regarding robotic autonomy and safety [4,5].

Yet, in this race to embrace innovation, it is worth pausing to ask: are we adopting robotic surgery because it meaningfully improves outcomes or because it looks and feels like the future?

3. What the Evidence Actually Shows

Despite growing adoption, the comparative literature presents a more mixed and less transformative picture than the technological enthusiasm surrounding RAC might suggest. The evidence base consists predominantly of retrospective cohorts and meta-analyses. The randomised crossover study cited in the earlier version evaluated novice performance in an ex vivo porcine model and should not be interpreted as a clinical randomised trial.

Conversion to open surgery is the clearest outcome currently favouring RAC. The recent meta-analysis by Qadri et al., incorporating 25 studies and approximately 1.77 million patients, found a lower pooled conversion rate with RAC (OR, 0.35; 95% CI, 0.31–0.41), although RAC required longer operative time. This finding deserves recognition, particularly in patients with a high baseline probability of conversion. Nevertheless, the absolute conversion rate is generally low, and much of the pooled evidence is observational; surgeon experience, institutional volume, and case selection therefore remain important potential modifiers [7].

Postoperative complications, too, were statistically similar between the two approaches. Common concerns such as bile duct injury, infection, or hernia formation occurred at comparable rates. Notably, while one randomised study did suggest RAC may reduce intraoperative mishaps in novice hands, the broader clinical implication remains uncertain. Less trauma during dissection is promising, but if it does not consistently translate to fewer complications postoperatively, the net benefit is debatable.

Evidence from acute care surgery is less favourable. In a cohort of 844,428 patients, Woldehana et al. found similar BDI rates after propensity matching, but RAC was associated with more major postoperative complications, greater postoperative drain use, and a longer hospital stay [14]. These findings suggest that a lower conversion rate does not necessarily translate into improved overall recovery or resource use, particularly in acute gallbladder disease.

The one domain where RAC consistently diverges is operative time—and not in its favour. Across pooled clinical studies, RAC has generally been associated with longer operative time, although the magnitude varies with case definition, surgeon experience, docking efficiency, and institutional workflow. Qadri et al. reported a pooled mean difference of 12.65 min favouring LC. By contrast, the experimental study by Willuth et al. found no difference between RAC and LC among novices in an ex vivo model (77.0 vs. 75.5 min; p = 0.517), further illustrating why training studies should not be conflated with comparative clinical evidence [7,15]. The reasons are multifactorial: system docking, port placement, learning curves, and equipment troubleshooting all contribute. While these inefficiencies may diminish with experience and technological refinement, they remain a practical concern—especially in high-volume surgical environments.

Bile duct injury requires separate consideration because a rare outcome may be obscured within composite complication measures. In the Medicare analysis by Kalata et al., BDI requiring definitive operative repair occurred more frequently after RAC than LC (0.7% vs. 0.2%; RR, 3.16). An instrumental-variable analysis intended to reduce unmeasured confounding produced a smaller but still significant difference (0.4% vs. 0.2%; RR, 1.88). A subsequent analysis by Mullens et al. found an approximately threefold higher BDI risk with RAC across low-, medium-, and high-risk groups, making patient complexity alone an unlikely explanation [16,17].

The learning curve is a plausible contributor. Sheetz et al. found that 87% of surgeons performed fewer than 10 RAC procedures and estimated that 300–450 procedures might be required to reach the average BDI rate associated with LC. However, claims-based studies cannot capture detailed anatomy, critical-view attainment, trainee participation, fluorescence use, credentialing, or other operative factors. The increased BDI signal therefore cannot be attributed exclusively to the learning curve, but neither should it be dismissed as case-selection bias. Under current real-world implementation conditions, it remains a potential drawback of RAC [12].

Taken together, the evidence does not support a simple claim that RAC is either equivalent or uniformly inferior to LC. RAC may reduce conversion in selected settings, but it has not demonstrated consistent improvement in common postoperative outcomes, generally requires more operative time and resources, and carries unresolved real-world safety concerns. For routine cases in which LC already performs exceptionally well, the remaining opportunity for meaningful incremental benefit is consequently small.

4. Beyond the Operating Field: Cost, Workflow, and Opportunity Cost

If RAC does not consistently improve the major clinical endpoints that matter most to patients—bile duct injury, postoperative complications, conversion to open surgery, length of stay, or recovery—then its value must be judged through a broader lens. In a routine operation such as cholecystectomy, equivalence is not necessarily enough. A new platform may be technologically impressive and still fail to justify itself if it increases cost, prolongs workflow, or diverts resources from procedures where robotic technology offers a clearer advantage.

The economic discussion surrounding RAC is often difficult because the true cost of robotic surgery extends beyond the single operation. Acquisition of the platform, maintenance contracts, instrument use, disposable supplies, staff training, operating room turnover, and surgeon learning curves all contribute to the institutional burden. These costs are not always visible to patients and may not be captured fully in procedure-level comparisons. Even when robotic systems are already available within a hospital, each additional robotic case consumes equipment time, specialised staff attention, and operating room capacity that could be used elsewhere.

Recent cost analyses reinforce this concern. In comparative evaluations, LC has generally remained less expensive than RAC, while postoperative outcomes have often been similar [18]. A large health-system analysis of more than 14,000 cholecystectomies found that disposable costs were substantially higher for robotic procedures, with no meaningful difference in readmissions, length of stay, 30-day reintervention, or mean operating room time between platforms [19]. Although robotic surgery may reduce conversion in some settings, the absolute event rate is low; therefore, the cost required to prevent one conversion may be substantial. This matters because conversion to open surgery, while important, is only one component of value. A platform that reduces a rare outcome but increases cost for every routine case must demonstrate that the tradeoff is meaningful at the patient, institutional, and health-system levels.

The economic effect of RAC is nevertheless context-dependent. High-volume institutions with mature robotic programs may distribute acquisition, maintenance, and training costs across a larger procedural volume and may reduce docking and turnover inefficiencies through stable, experienced teams. These conditions can narrow the cost difference, although they do not eliminate the additional disposable and platform-related costs associated with individual robotic procedures.

Importantly, economic value may differ between routine and complex gallbladder disease. In a recent academic referral-centre cohort, Caldwell et al. found that robotic complex elective cholecystectomy had higher operating-room costs but fewer unplanned postoperative biliary or interventional-radiology procedures, resulting in similar total costs of care. In noncomplex cases, RAC produced no postoperative advantage and remained more expensive overall. Although these single-centre observational findings require external validation, they illustrate the type of selective added value that may justify RAC more convincingly than routine use [20].

Workflow is equally important. Operative time is not merely a technical variable; it is a practical resource. Additional minutes may reflect docking, positioning, troubleshooting, instrument exchange, and team coordination. In high-volume settings, small differences in operative or turnover time can accumulate into fewer cases completed, longer staff hours, and greater pressure on already strained perioperative systems. For a complex hepatobiliary operation, this tradeoff may be acceptable. For a straightforward elective cholecystectomy, the threshold should be higher.

The adoption pattern of robotic surgery also deserves scrutiny. Robotic platforms tend to diffuse rapidly once introduced, including into common procedures for which conventional laparoscopy is already safe, mature, and efficient [12]. This creates a subtle but important risk: technology begins to shape the indication rather than the indication shaping the technology. Hospitals may feel pressure to use the robot after purchasing it, while surgeons may seek opportunities to maintain robotic proficiency, and patients may associate robotics with superior care because of institutional marketing. None of these motivations is inherently inappropriate, but none should substitute for evidence of added value.

For this reason, RAC should not be evaluated only as a question of technical feasibility. It is clearly feasible. The more relevant question is whether it provides enough incremental benefit to justify its incremental cost and operational complexity. In routine cholecystectomy, the answer remains uncertain. Until stronger value-based evidence emerges, the default assumption should not be that robotic surgery is the natural successor to LC but that it is a selective tool whose use should be justified case by case.

5. Where Robotic Cholecystectomy May Still Have a Role

A cautious position on RAC should not be mistaken for a rejection of robotic surgery. The issue is not whether robotic platforms have value in modern surgery; they clearly do. The issue is whether routine cholecystectomy is the setting in which that value is most consistently realised. The answer may depend less on the operation’s name and more on patient selection, surgeon experience, institutional context, and the specific problem the robot is being used to solve.

First, RAC may have a role in selected difficult gallbladder cases. Severe inflammation, dense adhesions, distorted anatomy, obesity, prior upper abdominal surgery, or subtotal/bailout scenarios may create technical challenges in which improved dexterity, stable visualisation, and enhanced instrument articulation are helpful. Emerging observational data suggest that robotic surgery may be viable in difficult gallbladders and may reduce selected intraoperative challenges in experienced hands [21]. However, this potential benefit should be interpreted carefully. Difficult cases are heterogeneous, and the choice of approach may be influenced by surgeon comfort, institutional experience, case timing, and availability of the robotic platform. A difficult gallbladder in a high-volume robotic centre is not the same clinical situation as a routine elective gallbladder removed robotically in a low-volume environment.

Kawka et al. reported potentially fewer complications and conversions with RAC in difficult gallbladder cases, but the study included only 88 patients, was retrospective, and involved a tertiary-centre practice. The results support feasibility and hypothesis generation rather than a definitive indication for RAC.

Second, robotic platforms may offer educational value. For novice surgeons, the robotic console provides ergonomic positioning, three-dimensional visualisation, tremor filtration, and controlled instrument motion. Experimental work has suggested that novices may perform certain cholecystectomy-related tasks better using robotic assistance than conventional laparoscopy [15]. This is an important finding, but it should not be overextended. Performance in an ex vivo or simulated model does not automatically translate into safer patient outcomes. If RAC is used as a training procedure, programmes must ensure that the learning curve does not shift risk onto patients. Structured curricula, proctoring, simulation, stepwise autonomy, and outcome monitoring are essential.

Third, RAC may serve as a bridge to more complex robotic surgery. Institutions that perform advanced robotic procedures may use cholecystectomy as a low-acuity case for team familiarisation, workflow development, and surgeon comfort. This argument has practical merit, but it is ethically and operationally different from claiming that RAC is superior for the cholecystectomy patient. If the purpose is training, that purpose should be explicit, supervised, and justified. A patient should not receive a more expensive or potentially longer procedure simply because it is convenient for institutional skill maintenance.

Selective clinical use should not mean abandoning the development of robotic expertise. The appropriate distinction is between structured training and unstructured diffusion. Proficiency can be developed through simulation, laboratory training, dual-console instruction, proctoring, supervised low-complexity cases, graduated autonomy, and prospective outcome monitoring. Routine cases may have a role within an explicit and supervised credentialing pathway, but accumulating volume without structured oversight effectively asks patients to absorb the learning curve. The goal should therefore be to restrict unmonitored adoption, not access to robotic training.

Finally, some advantages attributed to RAC may actually arise from adjunct technologies rather than the robotic platform itself. Near-infrared fluorescent cholangiography with indocyanine green, for example, may improve biliary structure visualisation and has been studied in both laparoscopic and robotic settings [21,22]. If improved safety comes from better biliary mapping, then the question becomes whether that benefit requires a robotic platform or whether similar gains can be achieved through laparoscopic fluorescence imaging. Future studies should be careful not to attribute the benefit of visual adjuncts to robotics alone.

Thus, the most defensible position is neither “robots for everyone” nor “robots for no one.” The better question is: for which patients, in which institutions, and under which surgeon-experience conditions does RAC provide value beyond LC? Until that question is answered, RAC should be considered a selective option rather than a routine replacement.

Current evidence does not establish an absolute indication for RAC. LC should remain the reference approach for routine, uncomplicated disease. RAC may be selectively reasonable when technical difficulty is anticipated—particularly after an aborted or partial cholecystectomy, in the presence of a cholecystostomy tube, following gallbladder perforation or fistula, or in cases involving severe inflammation and distorted anatomy—provided that an experienced robotic surgeon and a stable team are available. Robotic-platform availability should not delay treatment or supersede critical-view principles, subtotal cholecystectomy, or conversion when required for safety.

6. What Evidence Would Change the Conversation?

The current debate around RAC often begins with the wrong question: “Can the robot perform the operation?” The answer is yes. The more meaningful question is, “Does the robot improve the outcome that matters for the patient who needs the operation at a cost and workflow burden the health system can justify?” This shift from feasibility to value should guide the next generation of research.

Future studies should move beyond broad comparisons of RAC versus LC and instead examine clinically relevant subgroups. Routine elective cholecystectomy, acute cholecystitis, gangrenous cholecystitis, obesity, prior abdominal surgery, difficult Calot’s triangle, subtotal cholecystectomy, and interval cholecystectomy after percutaneous drainage may represent very different populations. Pooling these cases together can obscure both benefit and harm. If RAC is advantageous, it is unlikely to be equally advantageous across all gallbladders.

Surgeon experience also requires more explicit measurement. A robotic operation performed by a surgeon early in the learning curve should not be analysed as equivalent to one performed by a mature robotic surgeon with a stable team. Similarly, LC is not a generic comparator; outcomes vary by surgeon experience, institutional volume, assistant skill, and adherence to safe cholecystectomy principles. Future research should report surgeon and team experience, prior robotic case volume, docking and console time, use of intraoperative cholangiography or fluorescence imaging, and whether bailout strategies were used.

Cost-effectiveness analyses should also become more rigorous and transparent. The relevant outcome is not simply operating room charge or hospital bill. A meaningful analysis should include capital amortisation, maintenance, disposable instruments, staffing, training, operative time, turnover time, length of stay, readmissions, reoperations, management of bile duct injury, and opportunity cost.

The ideal evidence base would include multicentre pragmatic trials or high-quality prospective registries that compare RAC and LC across defined risk groups, account for learning curves, and incorporate both clinical and economic endpoints. Because randomised trials may be difficult in this area due to surgeon preference, patient perception, and institutional investment, carefully designed registry-based studies may be especially useful. However, such studies must avoid the common trap of simply asking whether RAC is “noninferior.” For an established, safe, efficient, and inexpensive procedure such as LC, noninferiority may not be sufficient. The proper threshold should be added value.

Until such evidence exists, RAC should be adopted with humility. The goal is not to prevent surgeons from acquiring robotic expertise or to slow innovation. It is to link adoption to structured training, defined clinical problems, and transparent outcome evaluation. For RAC, the decisive question is not whether the robot can perform cholecystectomy but whether it solves a problem that laparoscopy does not. The future of RAC should therefore depend not on the allure of the platform but on a more precise answer to a simple question: what problem does the robot solve here that laparoscopy does not?

7. Conclusions

RAC should not become the default successor to LC simply because it is technically feasible or increasingly available. Current evidence supports a narrower role: LC remains the reference approach for routine cases, whereas RAC may provide added value in selected complex cases and mature programs if safety, learning curve, and full-cost outcomes are measured transparently. The next phase should be selective adoption linked to structured training and prospective evaluation—not diffusion first and justification later. Progress in surgery should be defined not by how advanced our tools appear but by how meaningfully they improve care.